PHILOGEN S.P.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.05 EUR | -.--% |
|
-0.55% | -2.43% |
| 12/04 | Indices up; Italy, industrial sales down | AN |
| 03/04 | Transcript : Philogen S.p.A., 2023 Earnings Call, Apr 03, 2024 |
| Sales 2024 * | 85.68M 91.8M 7.66B | Sales 2025 * | 20.9M 22.39M 1.87B | Capitalization | 727M 779M 65.03B |
|---|---|---|---|---|---|
| Net income 2024 * | 3M 3.21M 268M | Net income 2025 * | -46M -49.28M -4.11B | EV / Sales 2024 * | 7.69 x |
| Net cash position 2024 * | 68.24M 73.11M 6.1B | Net cash position 2025 * | 67.01M 71.8M 5.99B | EV / Sales 2025 * | 31.6 x |
| P/E ratio 2024 * |
201
x | P/E ratio 2025 * |
-15.8
x | Employees | 165 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 27.79% |
More Fundamentals
* Assessed data
More news
Latest transcript on Philogen S.p.A.
More press releases
More news
| 1 week | -0.55% | ||
| Current month | +2.56% | ||
| 1 month | +2.56% | ||
| 3 months | +5.25% | ||
| 6 months | +2.56% | ||
| Current year | -2.43% |
1 week
17.85
18.75
1 month
17.3018.75
Current year
16.3018.75
1 year
14.6019.25
3 years
12.6019.25
5 years
12.6019.25
10 years
12.6019.25
| Managers | Title | Age | Since |
|---|---|---|---|
Dario Neri
CEO | Chief Executive Officer | 61 | 01/96/01 |
Duccio Neri
FOU | Founder | 61 | 01/96/01 |
Laura Baldi
DFI | Director of Finance/CFO | 52 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 68 | - | |
| Director/Board Member | 55 | - | |
Duccio Neri
FOU | Founder | 61 | 01/96/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/24/30 | 18.05 | -0.28% | 1,689 |
| 29/24/29 | 18.1 | -.--% | 56,334 |
| 26/24/26 | 18.1 | -0.28% | 55,589 |
| 25/24/25 | 18.15 | +1.68% | 2,536 |
| 24/24/24 | 17.85 | -2.19% | 78,687 |
Real-time Borsa Italiana, April 30, 2024 at 09:14 pm IST
More quotes
Philogen SpA is an Italy-based company, operating in the biotechnology sector. The Company develops products and technologies for the diagnosis and therapy of serious human diseases. It has three anti-cancer antibody derivatives, produced with an in-house industrial process, into Phase I/II clinical studies. The majority of its technologies and products are based on high-affinity human monoclonal antibody fragments. Philogen SpA developed a patented technology, Iterative Colony Filter Screening, for the isolation of monoclonal antibodies, which requires neither immunization nor phage display. The Company's subsidiaries are Philotec, Philomed and Philochem. Philogen SpA is headquartered in Siena, Italy.
Calendar
07/05/2024
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
18.05
EUR
Average target price
23.5
EUR
Spread / Average Target
+30.19%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -2.43% | 778M | |
| -1.17% | 102B | |
| +2.87% | 96.09B | |
| +2.13% | 22.28B | |
| -14.77% | 21.4B | |
| -8.79% | 18.14B | |
| -39.98% | 17.02B | |
| -13.21% | 16.09B | |
| +8.55% | 13.83B | |
| +35.75% | 11.97B |
- Stock Market
- Equities
- PHIL Stock
